Comparison of aripiprazole augmentation versus bupropion combination for patient with major depressive disorder

被引：1

作者：

Lee, K. ^{[1
]}

Lee, J. B. ^{[2
]}

Park, Y. W. ^{[3
]}

Lee, J. H. ^{[4
]}

Lee, S. J. ^{[5
]}

Koo, B. H. ^{[5
]}

Sung, H. M. ^{[6
]}

Cheon, E. J. ^{[5
]}

机构：

[1] Dongguk Univ Hosp, Psychiat, Gyeongjy, South Korea

[2] Yeungnam Univ Hosp, Psychiat, Daegu, South Korea

[3] Fatima Hosp, Psychiat, Daegu, South Korea

[4] Catholic Univ Daegu Hosp, Psychiat, Daegu, South Korea

[5] Kyungpook Univ Hosp, Psychiat, Daegu, South Korea

[6] Cha Univ Hosp, Psychiat, Gumi, South Korea

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷

关键词：

D O I：

10.1016/S0924-977X(14)70724-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.2.f.003

引用

页码：S452 / S453

页数：2

共 50 条

[21] Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder [J].

Chernoloz, Olga ;

El Mansari, Mostafa ;

Blier, Pierre .

PSYCHOPHARMACOLOGY, 2009, 206 (02) :335-344

[22] Aripiprazole-Related Subcortical Growth in a Patient With Major Depressive Disorder and Panic Disorder [J].

Lai, Chien-Han .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (04) :474-476

[23] The tolerability and safety of bupropion XL versus escitaloprani in the treatment of major depressive disorder [J].

Horrigan, J ;

Wightman, D ;

Modell, J .

EUROPEAN PSYCHIATRY, 2005, 20 :S144-S145

[24] Clinical correlates of augmentation/combination treatment strategies in major depressive disorder [J].

Dold, M. ;

Bartova, L. ;

Mendlewicz, J. ;

Souery, D. ;

Serretti, A. ;

Porcelli, S. ;

Zohar, J. ;

Montgomery, S. ;

Kasper, S. .

ACTA PSYCHIATRICA SCANDINAVICA, 2018, 137 (05) :401-412

[25] The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study [J].

Han, Changsu ;

Wang, Sheng-Min ;

Bahk, Won-Myong ;

Lee, Soo-Jung ;

Patkar, Ashwin A. ;

Masand, Prakash S. ;

Pae, Chi-Un .

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2019, 17 (04) :495-502

[26] Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder [J].

Kamijima, Kunitoshi ;

Yasuda, Moriyoshi ;

Yamamura, Kayo ;

Fukuta, Yasuhiko .

CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (12) :2105-2112

[27] Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder [J].

Papakostas, GI ;

Petersen, TJ ;

Kinrys, G ;

Burns, AM ;

Worthington, JJ ;

Alpert, JE ;

Fava, M ;

Nierenberg, AA .

JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (10) :1326-1330

[28] Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder [J].

Shin, Cheolmin ;

Pae, Chi-Un ;

Kwak, Kyung Phil ;

Jeon, Sang Won ;

Jeong, Hyun-Ghang ;

Kim, Jong-Woo ;

Lee, Youn Jung ;

Patkar, Ashwin A. ;

Han, Changsu .

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021, 19 (02) :243-253

[29] Efficacy and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder [J].

Shin, D. ;

Hong, S. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 :S300-S300

[30] The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting [J].

Lee, Seung-Hoon ;

Lee, Kyung Ho ;

Han, Tae Sun ;

Han, Changsu ;

Bahk, Won-Myong ;

Lee, Soo-Jung ;

Patkar, Ashwin A. ;

Masand, Prakash S. ;

Pae, Chi-Un .

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2024, 22 (02) :370-375

← 1 2 3 4 5 →